Back to top
more

Rani Therapeutics (RANI)

(Delayed Data from NSDQ)

$6.68 USD

6.68
42,066

+0.12 (1.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.69 +0.01 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Rani Therapeutics Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 49 99 117 73 -99,999
Receivables 0 0 0 2 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 2 2 2 0 NA
Total Current Assets 51 101 120 75 NA
Net Property & Equipment 6 6 5 4 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 0 0 0 0 NA
Total Assets 58 108 124 79 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 NA
Accounts Payable 1 1 1 1 NA
Current Portion Long-Term Debt 5 0 0 1 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 2 2 1 1 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 0 0 0 3 NA
Total Current Liabilities 8 5 3 5 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 24 29 0 2 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 32 34 3 8 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 185 NA
Common Stock (Par) 0 0 0 1 NA
Capital Surplus 86 76 56 0 NA
Retained Earnings -73 -39 -8 -114 NA
Other Equity 13 37 74 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 25 74 122 71 NA
Total Liabilities & Shareholder's Equity 58 108 124 79 NA
Total Common Equity 25 74 122 -113 0
Shares Outstanding 50.10 49.40 49.00 NA NA
Book Value Per Share 0.51 1.50 2.48 0.00 0.00

Fiscal Year End for Rani Therapeutics Holdings, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 49 61 75 87
Receivables NA 0 3 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 2 0 2 2
Total Current Assets NA 51 63 76 89
Net Property & Equipment NA 6 6 6 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 58 70 84 96
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 1 1 1 2
Current Portion Long-Term Debt NA 5 1 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 2 4 4 3
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 8 7 6 5
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 24 28 29 29
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 32 36 35 35
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 86 83 81 78
Retained Earnings NA -73 -66 -57 -47
Other Equity NA 13 17 24 31
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 25 35 48 62
Total Liabilities & Shareholder's Equity NA 58 70 84 96
Total Common Equity 0 25 35 48 62
Shares Outstanding 50.10 50.10 49.90 49.60 49.40
Book Value Per Share 0.00 0.51 0.70 0.97 1.25